AR028968A1 - Derivados heterociclicos de la aminoalquilpiridina como psicofarmacos - Google Patents

Derivados heterociclicos de la aminoalquilpiridina como psicofarmacos

Info

Publication number
AR028968A1
AR028968A1 ARP010102933A ARP010102933A AR028968A1 AR 028968 A1 AR028968 A1 AR 028968A1 AR P010102933 A ARP010102933 A AR P010102933A AR P010102933 A ARP010102933 A AR P010102933A AR 028968 A1 AR028968 A1 AR 028968A1
Authority
AR
Argentina
Prior art keywords
hal
groups
optionally
ring structures
mono
Prior art date
Application number
ARP010102933A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR028968A1 publication Critical patent/AR028968A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados heterocíclicos de la aminoalquilpiridina de la formula (1) donde R1 es el radical de un heterociclo con 1 a 3 estructuras de anillo, donde cada estructura de anillo es saturada, no saturada o aromática, y opcionalmente está fusionada con otras estructuras de anillo para dar un sistema de anillos condensado, presentando el heterociclo un total de 1 a 4 átomos de N, O y/o S en las estructuras de anillo y opcionalmente está mono-, bi- o trisustituido por uno o varios de los grupos ûA, -OR4, -N(R4)2, -NO2, -CN, Hal, -COOR4, -CON(R4)2, -COR4, =O; R2 es un grupo fenilo, opcionalmente mono -, bi- tri ûtetra o pentasustituido por uno o varios de los grupos Hal, A, -O-A, -NO2 o ûCN, o bien un grupo tienilo, opcionalmente mono o bisustituido con uno o varios de los grupos Hal, A, -O-A, -NO2, -CN o tienilo; -X- es ûO-, -S-, sulfinilo, sulfonilo, -C(R4)2; -Y- es [C(R4)2]n-; -Z- es ûC(R4)2; n es 1, 2, 3 o 4; así como sus sales y solvatos compatibles y su uso como medicamento.
ARP010102933A 2000-06-20 2001-06-20 Derivados heterociclicos de la aminoalquilpiridina como psicofarmacos AR028968A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10029371A DE10029371A1 (de) 2000-06-20 2000-06-20 Heterocyclische Aminoalkylpyridinderivate als Psychopharmaka

Publications (1)

Publication Number Publication Date
AR028968A1 true AR028968A1 (es) 2003-05-28

Family

ID=7645750

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102933A AR028968A1 (es) 2000-06-20 2001-06-20 Derivados heterociclicos de la aminoalquilpiridina como psicofarmacos

Country Status (21)

Country Link
US (1) US6960599B2 (es)
EP (1) EP1292592B1 (es)
JP (1) JP5160715B2 (es)
KR (1) KR20030011092A (es)
CN (1) CN1437595A (es)
AR (1) AR028968A1 (es)
AT (1) ATE506357T1 (es)
AU (2) AU7845701A (es)
BR (1) BR0111816A (es)
CA (1) CA2410594C (es)
CZ (1) CZ20023955A3 (es)
DE (2) DE10029371A1 (es)
ES (1) ES2363668T3 (es)
HU (1) HUP0301316A2 (es)
MX (1) MXPA02012262A (es)
NO (1) NO20026104L (es)
PL (1) PL358672A1 (es)
RU (1) RU2003100514A (es)
SK (1) SK17122002A3 (es)
WO (1) WO2001098293A1 (es)
ZA (1) ZA200209727B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800652B2 (en) 2002-08-16 2004-10-05 Pfizer Inc. Diaryl compounds
GB0219154D0 (en) * 2002-08-16 2002-09-25 Pfizer Ltd Diaryl compounds
DE10254596A1 (de) * 2002-11-22 2004-06-03 Merck Patent Gmbh Indolderivate
US8030336B2 (en) * 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
KR100679480B1 (ko) * 2004-05-18 2007-02-07 엄기형 지하층 바닥에 시공되는 배수판
US8152380B2 (en) * 2006-07-07 2012-04-10 Federal-Mogul World Wide, Inc. Sleeve bearing assembly and method of construction
KR101043454B1 (ko) * 2009-07-10 2011-06-23 현대산업개발 주식회사 건축 지하구조물의 마감 조립체
US9012651B2 (en) * 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5177088A (en) 1991-04-17 1993-01-05 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 3-(pyridinylamino)-indoles
TW203047B (es) * 1991-06-21 1993-04-01 American Home Prod
JPH05125024A (ja) * 1991-11-05 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアリールオキシアルキルアミン誘導体又はその塩
JPH05255302A (ja) * 1992-03-09 1993-10-05 Yamanouchi Pharmaceut Co Ltd 新規なクロマニルオキシアルキルアミン誘導体
DE4226527A1 (de) * 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
JPH07309867A (ja) * 1994-05-19 1995-11-28 Asahi Chem Ind Co Ltd トリプタミン誘導体およびその用途
SI0707007T1 (en) 1994-10-14 2002-04-30 Merck Patent Gmbh (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)chromane as CNS active agent
JPH0940648A (ja) * 1995-08-02 1997-02-10 Yamanouchi Pharmaceut Co Ltd 新規な8−(2−アミノアルコキシ)キノリン誘導体
DK0923548T3 (da) * 1996-08-27 2003-06-23 Wyeth Corp 4-Aminoethoxyindoler som dopamin-D2-agonister og som 5HT 1A-ligander

Also Published As

Publication number Publication date
CA2410594A1 (en) 2001-12-27
NO20026104D0 (no) 2002-12-19
ES2363668T3 (es) 2011-08-11
MXPA02012262A (es) 2003-04-25
NO20026104L (no) 2002-12-19
BR0111816A (pt) 2003-06-24
PL358672A1 (en) 2004-08-09
EP1292592A1 (de) 2003-03-19
DE10029371A1 (de) 2002-01-03
WO2001098293A1 (de) 2001-12-27
CN1437595A (zh) 2003-08-20
US20040019044A1 (en) 2004-01-29
HUP0301316A2 (hu) 2003-08-28
JP2004501148A (ja) 2004-01-15
US6960599B2 (en) 2005-11-01
DE50115858D1 (de) 2011-06-01
AU7845701A (en) 2002-01-02
JP5160715B2 (ja) 2013-03-13
AU2001278457C1 (en) 2002-01-02
RU2003100514A (ru) 2004-07-20
ATE506357T1 (de) 2011-05-15
AU2001278457B2 (en) 2006-10-19
KR20030011092A (ko) 2003-02-06
EP1292592B1 (de) 2011-04-20
ZA200209727B (en) 2004-03-30
CZ20023955A3 (cs) 2003-05-14
CA2410594C (en) 2010-10-26
SK17122002A3 (sk) 2003-04-01

Similar Documents

Publication Publication Date Title
ES2721268T3 (es) Compuestos de pirazolo[1,5-a]pirimidina-5,7-diamina como inhibidores de CDK y su uso terapéutico
AR011101A1 (es) Compuesto derivado de acidos arilsulfonilaminohidroxiamicos y composicion farmaceutica que lo contiene
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
ECSP066898A (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
AR043466A1 (es) Proceso de un solo paso para la preparacion de derivados anticonvulsivos
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
AR091400A2 (es) Composicion farmaceutica que comprende derivados de sulfamida, proceso para prepararla y uso de dichos compuestos para preparar medicamentos
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
BR0114657A (pt) Compostos de benzamida e seu uso
AR028968A1 (es) Derivados heterociclicos de la aminoalquilpiridina como psicofarmacos
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR051753A1 (es) Metodos para preparar compuestos de indazol
ES2192081T3 (es) Derivados de purina antivirales.
AR041271A1 (es) Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
AR033678A1 (es) Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
AR019365A1 (es) Compuesto de 1-piperidin-3-fenil-butil-naftamida, proceso para prepararlo, composicion farmaceutica y uso para fabricar un medicamento util para eltratamiento de una enfermedad por antagonistas de taquicininas neuropeptidicas endogenas
DK0639179T3 (da) 23-oxaderivater i D-vitaminserien, fremgangsmåde til fremstilling heraf, farmaceutiske præparater indeholdende disse derivater samt deres anvendelse som lægemidler
AR035570A1 (es) Derivados de isotiazol
AR042439A1 (es) Concentrado para suspender en aceites
AR039780A1 (es) Ligandos receptores de melanocortina
AR037502A1 (es) Compuesto de 6,7-dihidro-5h-pirazolo[1,2a]pirazol-1-ona espirociclico y su uso para fabricar una composicion farmaceutica
ES2115220T3 (es) Nuevo uso de compuestos bis-heterociclicos como agentes antiinflamatorios y composiciones farmaceuticas de los mismos.
CO5040177A1 (es) Composiciones y sales de n-alquilamonio acetonitrilo y meto- do para fabricarlas
AR021542A1 (es) Un compuesto de sulfonamida y las composiciones y preparaciones farmaceuticas que lo contienen
AR036108A1 (es) Derivados de oxadiazol, respectivamente de tiadiazol-pirrolidina, uso de dichos derivados en la preparacion de composiciones para modular, bloquear o antagonizar la actividad de oxitocina con sus receptores y/o el tratamiento y/o prevencion de enfermedades mediadas por la oxitocina , inclusive en la

Legal Events

Date Code Title Description
FB Suspension of granting procedure